Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
Crossref DOI link: https://doi.org/10.1007/s10549-016-4009-3
Published Online: 2016-10-17
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cazzaniga, M. E.
,
Cortesi, L.
Ferzi, A.
Scaltriti, L.
Cicchiello, F.
Ciccarese, M.
Della Torre, S.
Villa, F.
Giordano, M.
Verusio, C.
Nicolini, M.
Gambaro, A. R.
Zanlorenzi, L.
Biraghi, E.
Legramandi, L.
Rulli, E.
License valid from 2016-10-17